Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice

Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice

Background: Although imatinib is a well-established first-line drug for treating a vast majority of gastrointestinal stromal tumours (GIST), GISTs acquire secondary resistance during therapy. Multi-omics approaches provide an integrated perspective to empower the development of personalised therapie...

Full description

Bibliographic Details
Main Authors: Szymon Macioszek, Danuta Dudzik, Rafał Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schöffski, Michał J. Markuszewski
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Translational Oncology
Subjects:
Metabolomics
Transcriptomics
Imatinib
GIST
purines
Multi-omics
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523323000189

Internet

http://www.sciencedirect.com/science/article/pii/S1936523323000189

Similar Items